Previous 10 | Next 10 |
2023-12-03 02:02:03 ET Summary Immix Biopharma is a biotech company focused on developing CAR-T and other cell-based therapies for cancers and heme disorders. Their most advanced project is NXC-201, a BCMA-targeted CAR-T natural killer cell therapy, which has shown a 95% overall r...
LOS ANGELES, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announc...
LOS ANGELES, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies for oncology and immunology, today announce...
2023-11-21 11:54:51 ET More on Immix Biopharma, Inc. Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum Immix Biopharma climbs on upcoming ASH readout Immix gains FDA orphan drug status for CAR-T therapy Seeking Alpha’s Quant R...
2023-11-21 11:47:03 ET More on Immix Biopharma Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum Immix Biopharma climbs on upcoming ASH readout Immix gains FDA orphan drug status for CAR-T therapy Seeking Alpha’s Quant Rating ...
NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance 72 patients previously dosed with NXC-201 ex-U.S. First CAR-T program for light-chain (AL) Amyloidosis Favorable tolerability enables expansion into autoimmune indication...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Immix Biopharma Inc. (IMMX) is expected to report $-0.23 for Q3 2023
2023-11-06 15:35:37 ET More on Immix Biopharma, Inc. Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum Immix gains FDA orphan drug status for CAR-T therapy Immix Biopharma director acquires $200K worth of shares Seeking Alpha’...
100% overall response rate observed in relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy Updated results will be communicated at the presentation time December 10, 2023 LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (...
News, Short Squeeze, Breakout and More Instantly...
Lead site Memorial Sloan Kettering Cancer Center (MSKCC) Timing of milestone in-line with mid-2024 guidance Data from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced...